2020
DOI: 10.21203/rs.3.rs-45664/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Long non-coding RNA LINC00115 contributes to the progression of colorectal cancer by targeting miR-489-3p via PI3K/AKT/mTOR pathway

Abstract: Background Long noncoding RNAs (lncRNAs) are tumor-related regulators and have been found to be involved in the underlying molecular mechanisms of colorectal cancer (CRC). However, the role of lncRNA LINC00115 during CRC progression is not entirely elucidated. Methods The expression of LINC00115 was analyzed in paired CRC tissue samples and its clinical significance was evaluated. The biological effects on CRC cells proliferation, apoptosis, migration, invasion and PI3K/AKT/mTOR signaling were assessed by Ce… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 32 publications
0
1
0
Order By: Relevance
“…Molecular mechanism studies show that LINC00115 promotes breast cancer metastasis by regulating miR-7 and KLF4 expression. In colorectal cancer, LINC00115 inhibits the PI3K/AKT/mTOR signaling pathway by downregulating miR-489-3p, highlighting the LINC00115/miR-489-3p axis as a potential therapeutic target for colorectal cancer metastasis (18). So anti-LINC00115 compounds or agents consequently targeting the PI3K/AKT/mTOR pathway might serve as novel therapeutic strategies for the colorectal cancer treatment.…”
Section: Introductionmentioning
confidence: 99%
“…Molecular mechanism studies show that LINC00115 promotes breast cancer metastasis by regulating miR-7 and KLF4 expression. In colorectal cancer, LINC00115 inhibits the PI3K/AKT/mTOR signaling pathway by downregulating miR-489-3p, highlighting the LINC00115/miR-489-3p axis as a potential therapeutic target for colorectal cancer metastasis (18). So anti-LINC00115 compounds or agents consequently targeting the PI3K/AKT/mTOR pathway might serve as novel therapeutic strategies for the colorectal cancer treatment.…”
Section: Introductionmentioning
confidence: 99%